These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 38630015

  • 1. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.
    Srivastava S, Basak U, Naghibi M, Vijayakumar V, Parihar R, Patel J, Jadon PS, Pandit A, Dargad RR, Khanna S, Kumar S, Day R.
    Gut Microbes; 2024; 16(1):2338322. PubMed ID: 38630015
    [Abstract] [Full Text] [Related]

  • 2. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study.
    Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kosikowski W, Szczerbiński M, Gantzel J, Cukrowska B.
    Nutrients; 2020 Jul 05; 12(7):. PubMed ID: 32635661
    [Abstract] [Full Text] [Related]

  • 3. [Long-term probiotic administration for irritable bowel syndrome: a legal need].
    Solovyeva OI, Nekrasova AS, Topalova IG, Ponomarenko VA, Tsurtsumiia DB, Ilyashevich IG.
    Ter Arkh; 2023 Oct 11; 95(8):679-685. PubMed ID: 38158905
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T, Zeng H, Long Y, Li X, Sun X, Lan Y, Gao L, Zhang L, Feng Z, Hou X.
    Trials; 2020 Jun 30; 21(1):597. PubMed ID: 32605578
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study.
    Lewis ED, Antony JM, Crowley DC, Piano A, Bhardwaj R, Tompkins TA, Evans M.
    Nutrients; 2020 Apr 21; 12(4):. PubMed ID: 32326347
    [Abstract] [Full Text] [Related]

  • 6. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.
    J Clin Gastroenterol; 2012 Mar 21; 46(3):220-7. PubMed ID: 22157240
    [Abstract] [Full Text] [Related]

  • 7. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study.
    Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kanarek E, Sowińska A, Cukrowska B.
    Nutrients; 2021 Feb 26; 13(3):. PubMed ID: 33652763
    [Abstract] [Full Text] [Related]

  • 8. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
    Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP.
    BMC Gastroenterol; 2018 May 25; 18(1):71. PubMed ID: 29801486
    [Abstract] [Full Text] [Related]

  • 9. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.
    Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, Martin FP, Cominetti O, Welsh C, Rieder A, Traynor J, Gregory C, De Palma G, Pigrau M, Ford AC, Macri J, Berger B, Bergonzelli G, Surette MG, Collins SM, Moayyedi P, Bercik P.
    Gastroenterology; 2017 Aug 25; 153(2):448-459.e8. PubMed ID: 28483500
    [Abstract] [Full Text] [Related]

  • 10. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, Kassam Z, Sadovsky RG, Elliott RJ, Budree S, Kim M, Keller MJ.
    Lancet Gastroenterol Hepatol; 2019 Sep 25; 4(9):675-685. PubMed ID: 31326345
    [Abstract] [Full Text] [Related]

  • 11. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.
    Martoni CJ, Srivastava S, Leyer GJ.
    Nutrients; 2020 Jan 30; 12(2):. PubMed ID: 32019158
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome.
    Martoni CJ, Srivastava S, Damholt A, Leyer GJ.
    World J Gastroenterol; 2023 Jul 28; 29(28):4451-4465. PubMed ID: 37576702
    [Abstract] [Full Text] [Related]

  • 13. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.
    Sisson G, Ayis S, Sherwood RA, Bjarnason I.
    Aliment Pharmacol Ther; 2014 Jul 28; 40(1):51-62. PubMed ID: 24815298
    [Abstract] [Full Text] [Related]

  • 14. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.
    Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K.
    Gastroenterology; 2017 Oct 28; 153(4):936-947. PubMed ID: 28625832
    [Abstract] [Full Text] [Related]

  • 15. The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel Syndrome-A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial.
    Skrzydło-Radomańska B, Prozorow-Król B, Kurzeja-Mirosław A, Cichoż-Lach H, Laskowska K, Majsiak E, Bierła JB, Agnieszka S, Cukrowska B.
    J Clin Med; 2023 Jul 22; 12(14):. PubMed ID: 37510953
    [Abstract] [Full Text] [Related]

  • 16. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial.
    Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, Castellaneta S, Barone M, Indrio F, Gobbetti M, De Angelis M.
    J Clin Gastroenterol; 2019 Mar 22; 53(3):e117-e125. PubMed ID: 29688915
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
    Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM.
    Am J Gastroenterol; 2006 Jul 22; 101(7):1581-90. PubMed ID: 16863564
    [Abstract] [Full Text] [Related]

  • 18. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study.
    Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK.
    Nutr J; 2016 Feb 27; 15():21. PubMed ID: 26922379
    [Abstract] [Full Text] [Related]

  • 19. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome.
    Sabaté JM, Iglicki F.
    World J Gastroenterol; 2022 Feb 21; 28(7):732-744. PubMed ID: 35317278
    [Abstract] [Full Text] [Related]

  • 20. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK, Talley NJ, Stoddard GJ, Verne GN.
    Dig Dis Sci; 2019 Mar 21; 64(3):838-845. PubMed ID: 30370492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.